All In Biotech

Drug Trial Radar · NCT07082920

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-95298177, an Antibody Drug Conjugate Targeting Prostate Specific Membrane Antigen, for Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

140

Planned (sponsor's estimate)

Start

Jul 7, 2025

Primary completion

Nov 30, 2027

Study completion Dec 30, 2027

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jul 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD of JNJ-7827834 and JNJ-95298177 with or without JNJ-87189401 is for treatment of participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of prostate cancer where the cancer has spread beyond the prostate and is resistant to hormonal therapy) in Part 2 (Dose expansion) of study.

Conditions

  • Prostatic Neoplasms

Interventions

  • JNJ-78278343Drug

    JNJ-78278343 will be administered intravenously.

  • JNJ-95298177Drug

    JNJ-95298177 will be administered intravenously.

  • JNJ-87189401Drug

    JNJ-87189401 will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) by SeverityTime frame: Up to 2 years 2 months
  2. Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)Time frame: Up To Day 22

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Columbia University Medical Center

    New York, New York · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • The Christie Nhs Foundation Trust

    Manchester, United Kingdom · Recruiting

  • Royal Marsden Hospital (Sutton)

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.